{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:01:50Z","timestamp":1791468110260,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015285","name":"Hebei Province Medical Science Research Key Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012505","name":"Hebei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82501609"],"award-info":[{"award-number":["82501609"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571534"],"award-info":[{"award-number":["82571534"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2023206107"],"award-info":[{"award-number":["H2023206107"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.intimp.2026.117433","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:44:16Z","timestamp":1789847056000},"page":"117433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Elevated ISG15 reinforces RIG-I\/MDA5-linked macrophage\u2013microglia crosstalk during blood\u2013brain barrier disruption in neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"190","author":[{"given":"Yunfeng","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2026.117433_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9451","key":"10.1016\/j.intimp.2026.117433_bb0010","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2026.117433_bb0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.117433_bb0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117433_bb0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.intimp.2026.117433_bb0030","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10206","key":"10.1016\/j.intimp.2026.117433_bb0035","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised, placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.intimp.2026.117433_bb0040","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.117433_bb0045","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117433_bb0050","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial","volume":"23","author":"Cree","year":"2024","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117433_bb0055","article-title":"Long-term efficacy and safety of satralizumab in patients with neuromyelitis optica spectrum disorder from the SAkuraMoon open-label extension study","volume":"12","author":"Bennett","year":"2025","journal-title":"Neurol.: Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.intimp.2026.117433_bb0060","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40120-024-00640-7","article-title":"Safety and effectiveness of satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 6-month interim analysis of post-marketing surveillance","volume":"13","author":"Yamamura","year":"2024","journal-title":"Neurol. Therapy"},{"issue":"3","key":"10.1016\/j.intimp.2026.117433_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40120-024-00597-7","article-title":"Network meta-analysis of ravulizumab and alternative interventions for the treatment of neuromyelitis optica spectrum disorder","volume":"13","author":"Clardy","year":"2024","journal-title":"Neurol. Therapy"},{"key":"10.1016\/j.intimp.2026.117433_bb0070","article-title":"Advances in the long-term treatment of neuromyelitis optica spectrum disorder","volume":"16","author":"Anderson","year":"2024","journal-title":"J. Central Nervous Syst. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2026.117433_bb0075","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117433_bb0080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12974-024-03305-2","article-title":"CD22 blockade exacerbates neuroinflammation in neuromyelitis optica spectrum disorder","volume":"21","author":"Zhang","year":"2024","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.intimp.2026.117433_bb0085","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41598-024-51759-4","article-title":"Early involvement of peripherally derived monocytes in inflammation in an NMO-like mouse model","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.117433_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1690767","article-title":"Peripheral blood immune inflammatory markers in neuromyelitis optica spectrum disorders","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117433_bb0095","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.3390\/ijms26083585","article-title":"Microglia\/macrophages in autoimmune demyelinating encephalomyelitis (multiple sclerosis\/neuromyelitis optica)","volume":"26","author":"Yamasaki","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"38","key":"10.1016\/j.intimp.2026.117433_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202500942","article-title":"Type I interferon signaling augments autoimmunity in neuromyelitis optica spectrum disorder","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2026.117433_bb0105","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.intimp.2026.117433_bb0110","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117433_bb0115","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s12276-022-00872-3","article-title":"The diverse repertoire of ISG15: more intricate than initially thought","volume":"54","author":"Kang","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2026.117433_bb0120","article-title":"When ISG15 is involved in inflammation","volume":"17","author":"Feng","year":"2026","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117433_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12020153","article-title":"Unveiling the multifaceted roles of ISG15: from immunomodulation to therapeutic frontiers","volume":"12","author":"Alvarez","year":"2024","journal-title":"Vaccines"},{"issue":"21","key":"10.1016\/j.intimp.2026.117433_bb0130","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1002\/1873-3468.70063","article-title":"Interferon-induced protein ISG15 in the central nervous system, quo vadis?","volume":"599","author":"Glass","year":"2025","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.intimp.2026.117433_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030538","article-title":"ISG15 and ISGylation in human diseases","volume":"11","author":"Mirzalieva","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2026.117433_bb0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12974-022-02618-4","article-title":"ISGylation is induced in neurons by demyelination driving ISG15-dependent microglial activation","volume":"19","author":"Clarkson","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"14","key":"10.1016\/j.intimp.2026.117433_bb0145","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2420190122","article-title":"MDA5 ISGylation is crucial for immune signaling to control viral replication and pathogenesis","volume":"122","author":"Sarkar","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.intimp.2026.117433_bb0150","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41564-021-00884-1","article-title":"ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity","volume":"6","author":"Liu","year":"2021","journal-title":"Nat. Microbiol."},{"issue":"20","key":"10.1016\/j.intimp.2026.117433_bb0155","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.molcel.2025.09.008","article-title":"The RIG-I-like receptor family of immune proteins","volume":"85","author":"van Huizen","year":"2025","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.intimp.2026.117433_bb0160","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","article-title":"RIG-I-like receptors: their regulation and roles in RNA sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117433_bb0165","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1038\/s41467-023-41028-9","article-title":"MAVS integrates glucose metabolism and RIG-I-like receptor signaling","volume":"14","author":"He","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2026.117433_bb0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117433_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111592","article-title":"ISG15 increases the apoptosis of \u03b2 cells in type 1 diabetes","volume":"127","author":"Liu","year":"2025","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.intimp.2026.117433_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/biof.70103","article-title":"ISG15 mediates oxidative stress modulation in T2DM patients by directly targeting PIK3R2","volume":"52","author":"He","year":"2026","journal-title":"BioFactors"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926012804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926012804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:24:48Z","timestamp":1791465888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926012804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"alternative-id":["S1567576926012804"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117433","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated ISG15 reinforces RIG-I\/MDA5-linked macrophage\u2013microglia crosstalk during blood\u2013brain barrier disruption in neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117433"}}